JT
FDMT icon

Jupiter Topco’s 4D Molecular Therapeutics FDMT Stock Holding History

Jupiter Topco’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$76.5M Buy
+5,746,289
New +$56M 0.03% 362

Other funds holding FDMT

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Jupiter Topco's FDMT Position: Q2 2026 in Review

Jupiter Topco opened a new position in 4D Molecular Therapeutics (FDMT) in Q2 2026: 5,746,289 shares worth $76.5M. The stake represents 0.03% of the portfolio and ranks #362 among its holdings.

149 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Jupiter Topco held 5,746,289 shares of 4D Molecular Therapeutics worth $76.5M as of Q2 2026.
  • 4D Molecular Therapeutics was a new Jupiter Topco position in Q2 2026.
  • 4D Molecular Therapeutics made up 0.03% of Jupiter Topco's portfolio in Q2 2026, its #362 holding.
  • 149 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Jupiter Topco's 13F filing for Q2 2026, filed 14 Aug 2026.